Short intervention program for individuals who attempted suicide in Sweden
A Randomized Clinical Study of "Attempted Suicide Short Intervention Program" in Swedish Healthcare - ASSIP
NA · Region Skane · NCT04746261
This study is testing a new short program for people in Sweden who have recently tried to take their own life to see if it can help prevent future attempts when combined with regular treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 460 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Region Skane (other) |
| Locations | 2 sites (Lund and 1 other locations) |
| Trial ID | NCT04746261 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the Attempted Suicide Short Intervention Program (ASSIP) as a treatment for individuals who have recently attempted suicide. Conducted across six psychiatric clinics in Sweden, the study will recruit 460 patients who will be randomized to receive ASSIP alongside standard treatment or standard treatment alone. The trial aims to assess the effectiveness of ASSIP in preventing future suicide attempts and to identify factors that may influence its success. Additionally, the study will explore the economic benefits of implementing ASSIP in healthcare settings.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have recently attempted suicide and are receiving psychiatric care.
Not a fit: Patients with psychotic illnesses, severe personality disorders, or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly reduce the risk of future suicide attempts among patients.
How similar studies have performed: Previous studies, including a randomized controlled trial in Switzerland, have shown promising results for ASSIP, indicating its potential effectiveness.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years. * Signed informed consent to participate in the study. * Contact with psychiatric health care after a suicide attempt within 3 months before the baseline visit * Booked meeting or visit in psychiatry or primary care after visit 1 Exclusion Criteria: * Psychotic illness with current delusions, hallucinations or other negative symptoms that may affect the therapy. * Known emotionally unstable personality disorder (ICD 10) noted in the medical record * Inability to undergo therapy without an interpreter * Mental retardation, dementia, or other circumstances that make it difficult to understand the meaning of participating in the study and giving informed consent.
Where this trial is running
Lund and 1 other locations
- Region Skåne, psykiatri & habilitering, psykiatriforskning skane, Vuxenpsykiatri Lud — Lund, Sweden (RECRUITING)
- Region Skåne, psykiatri & habilitering, psykiatriforskning skane,Vuxenpsykiatri Malmoe — Malmö, Sweden (NOT_YET_RECRUITING)
Study contacts
- Principal investigator: Åsa Westrin, professor — Region Skane
- Study coordinator: Åsa Westrin, MD, PhD
- Email: asa.westrin@med.lu.se
- Phone: +4670 624 38 87
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Suicide, Attempted